Sera Prognostics (NASDAQ:SERA) CFO Austin Aerts Sells 5,440 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 5,440 shares of the firm’s stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $2.08, for a total value of $11,315.20. Following the completion of the transaction, the chief financial officer owned 303,227 shares in the company, valued at $630,712.16. This represents a 1.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sera Prognostics Price Performance

Shares of SERA stock traded down $0.13 during trading hours on Wednesday, reaching $2.00. The company had a trading volume of 99,259 shares, compared to its average volume of 58,147. Sera Prognostics, Inc. has a 12 month low of $1.43 and a 12 month high of $4.09. The business has a fifty day simple moving average of $2.03 and a 200-day simple moving average of $2.56. The company has a market cap of $78.32 million, a price-to-earnings ratio of -3.08 and a beta of 0.94.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.07 million. Sera Prognostics had a negative return on equity of 41.02% and a negative net margin of 56,385.97%. On average, equities research analysts expect that Sera Prognostics, Inc. will post -0.58 earnings per share for the current year.

Institutional Trading of Sera Prognostics

Large investors have recently bought and sold shares of the company. Jane Street Group LLC purchased a new stake in Sera Prognostics in the fourth quarter worth $203,000. Barclays PLC increased its position in Sera Prognostics by 267.4% in the fourth quarter. Barclays PLC now owns 36,722 shares of the company’s stock worth $108,000 after buying an additional 26,726 shares during the last quarter. Two Sigma Investments LP purchased a new stake in Sera Prognostics in the third quarter worth $97,000. Qube Research & Technologies Ltd purchased a new stake in Sera Prognostics in the second quarter worth $92,000. Finally, Cetera Investment Advisers purchased a new stake in Sera Prognostics in the fourth quarter worth $74,000. 54.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on SERA shares. Craig Hallum started coverage on Sera Prognostics in a report on Thursday, June 4th. They set a “buy” rating and a $6.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sera Prognostics in a report on Friday, March 27th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Sera Prognostics presently has an average rating of “Moderate Buy” and an average target price of $5.50.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.